Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00515333
Status:
COMPLETED
Last Update Posted:
2008-02-20
First Post:
2007-08-10
Brief Title:
TRx0014 in Patients With Mild or Moderate Alzheimers Disease
Sponsor:
TauRx Therapeutics Ltd
Organization:
TauRx Therapeutics Ltd
Study Overview
Official Title:
An Exploratory Placebo-Controlled Dose-Ranging Study of the Effects of TRx0014 30 MG TID 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses 30 60 and 100 mg tid compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type Cognitive ability will be measured by the Alzheimers Disease Assessment Scale - cognitive subscale ADAS-cog The primary evaluation will be made at 24 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None